PHILADELPHIA--(BUSINESS WIRE)--iCeutica, a company creating branded medicines that provide meaningful clinical benefits to patients and providers, today announced positive top-line results from its Phase 1 trial of ICE 1201, a submicron version of metaxalone, a muscle relaxant indicated for the treatment of acute, painful musculoskeletal conditions. Trial results demonstrated improved oral bioavailability, decreased pharmacokinetic variability, more rapid absorption and decreased food effect, when compared to the currently marketed metaxalone product, SKELAXIN®. Both ICE 1201 and SKELAXIN® were well tolerated, with only mild adverse events reported.
Help employers find you! Check out all the jobs and post your resume.
